Unknown

Dataset Information

0

Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors.


ABSTRACT: Reduction of brain amyloid-? (A?) has been proposed as a therapeutic target for Alzheimer disease (AD), and microglial A? phagocytosis is noted as an A? clearance system in brains. Galantamine is an acetylcholinesterase inhibitor approved for symptomatic treatment of AD. Galantamine also acts as an allosterically potentiating ligand (APL) for nicotinic acetylcholine receptors (nAChRs). APL-binding site is located close to but distinct from that for acetylcholine on nAChRs, and FK1 antibody specifically binds to the APL-binding site without interfering with the acetylcholine-binding site. We found that in human AD brain, microglia accumulated on A? deposits and expressed ?7 nAChRs including the APL-binding site recognized with FK1 antibody. Treatment of rat microglia with galantamine significantly enhanced microglial A? phagocytosis, and acetylcholine competitive antagonists as well as FK1 antibody inhibited the enhancement. Thus, the galantamine-enhanced microglial A? phagocytosis required the combined actions of an acetylcholine competitive agonist and the APL for nAChRs. Indeed, depletion of choline, an acetylcholine-competitive ?7 nAChR agonist, from the culture medium impeded the enhancement. Similarly, Ca(2+) depletion or inhibition of the calmodulin-dependent pathways for the actin reorganization abolished the enhancement. These results suggest that galantamine sensitizes microglial ?7 nAChRs to choline and induces Ca(2+) influx into microglia. The Ca(2+)-induced intracellular signaling cascades may then stimulate A? phagocytosis through the actin reorganization. We further demonstrated that galantamine treatment facilitated A? clearance in brains of rodent AD models. In conclusion, we propose a further advantage of galantamine in clinical AD treatment and microglial nAChRs as a new therapeutic target.

SUBMITTER: Takata K 

PROVIDER: S-EPMC3001000 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors.

Takata Kazuyuki K   Kitamura Yoshihisa Y   Saeki Mana M   Terada Maki M   Kagitani Sachiko S   Kitamura Risa R   Fujikawa Yasuhiro Y   Maelicke Alfred A   Tomimoto Hidekazu H   Taniguchi Takashi T   Shimohama Shun S  

The Journal of biological chemistry 20101014 51


Reduction of brain amyloid-β (Aβ) has been proposed as a therapeutic target for Alzheimer disease (AD), and microglial Aβ phagocytosis is noted as an Aβ clearance system in brains. Galantamine is an acetylcholinesterase inhibitor approved for symptomatic treatment of AD. Galantamine also acts as an allosterically potentiating ligand (APL) for nicotinic acetylcholine receptors (nAChRs). APL-binding site is located close to but distinct from that for acetylcholine on nAChRs, and FK1 antibody speci  ...[more]

Similar Datasets

| S-EPMC7961090 | biostudies-literature
| S-EPMC2936449 | biostudies-literature
| S-EPMC6960326 | biostudies-literature
| S-EPMC4840641 | biostudies-literature
| S-EPMC3523180 | biostudies-literature
| S-EPMC6354393 | biostudies-literature
| S-EPMC2597474 | biostudies-literature
| S-EPMC4769750 | biostudies-literature
| S-EPMC4052327 | biostudies-literature
| S-EPMC8199771 | biostudies-literature